Here are four things to know:
1. The company intends to use the funds to expand the company’s manufacturing capacity, sales, research and development, clinical activities as well as to fund working capital.
2. ConforMIS develops customized joint replacement implants through its proprietary iFit Image-to-Implant technology platform. It currently offers knee implants, but is planning to submit an application for approval of its iTotal Hip, a customized hip implant.
3. Since 2004, ConforMIS has raised an aggregate of $330 million from the sale of preferred stock and the exercise of preferred stock warrants and common stock warrants and options.
4. JP Morgan and Deutsche Bank are acting as joint lead book runners on the deal.
More articles on devices:
Global surgical robot markets poised for rapid growth — 5 key trends
Medtronic sets its sights on China — 5 things to know
VertiFlex’s Superion device receives FDA PMA order: 4 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
